SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 95 filers reported holding SYROS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.46 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $443,000 | -43.9% | 372,208 | +53.7% | 0.06% | -40.4% |
| Q4 2021 | $789,000 | +60.0% | 242,132 | +119.4% | 0.10% | +98.0% |
| Q3 2021 | $493,000 | -35.8% | 110,337 | -21.7% | 0.05% | -41.9% |
| Q2 2021 | $768,000 | +58.4% | 140,991 | +117.5% | 0.09% | +7.5% |
| Q1 2021 | $485,000 | +152.6% | 64,830 | +133.6% | 0.08% | +263.6% |
| Q4 2019 | $192,000 | +3.2% | 27,756 | +38.3% | 0.02% | +4.8% |
| Q2 2019 | $186,000 | -47.2% | 20,070 | -48.0% | 0.02% | -41.7% |
| Q1 2019 | $352,000 | +20.1% | 38,563 | -26.7% | 0.04% | +5.9% |
| Q4 2018 | $293,000 | -69.8% | 52,577 | -35.4% | 0.03% | -37.0% |
| Q3 2018 | $969,000 | +142.2% | 81,377 | +107.7% | 0.05% | +170.0% |
| Q2 2018 | $400,000 | -71.7% | 39,177 | -64.0% | 0.02% | -73.3% |
| Q1 2018 | $1,414,000 | +489.2% | 108,900 | +568.1% | 0.08% | +368.8% |
| Q3 2017 | $240,000 | – | 16,300 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 3,139,895 | $23,486,000 | 4.50% |
| Samsara BioCapital, LLC | 2,189,199 | $14,769,000 | 2.72% |
| Bain Capital Life Sciences Investors, LLC | 5,785,036 | $43,272,000 | 2.45% |
| Omega Fund Management, LLC | 1,562,500 | $11,688,000 | 1.11% |
| Flagship Pioneering Inc. | 2,938,494 | $21,980,000 | 0.35% |
| EcoR1 Capital, LLC | 1,000,000 | $7,480,000 | 0.33% |
| Altium Capital Management LP | 126,702 | $948,000 | 0.26% |
| Nikko Asset Management Americas, Inc. | 5,042,009 | $37,714,000 | 0.18% |
| Artal Group S.A. | 1,025,000 | $7,667,000 | 0.14% |
| Orbimed Advisors | 1,837,500 | $13,745,000 | 0.13% |